Daylight-PDT in the treatment of actinic keratosis: a pilot study comparing two different light sensitizers

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-001389-40-FI

Enrollment

Registered

2014-01-14

Start date

2014-04-29

Completion date

Unknown

Last updated

2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

actinic keratoses of the scalp MedDRA version: 14.1 Level: PT Classification code 10000614 Term: Actinic keratosis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders

Interventions

Trade Name: Hexvix Product Name: Hexvix Pharmaceutical Form: Cream Trade Name: Metvix Product Name: Metvix Pharmaceutical Form: Cutaneous emulsion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Actinic keratoses on both sides of scalp or forehead Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20

Exclusion criteria

Exclusion criteria: pregnancy lactation

Design outcomes

Primary

Measure	Time frame
Main Objective: Comparing the histological and clinical efficacy of two light sensitizers in the daylight-PDT treatment of actinic keratosis;Secondary Objective: Measuring changes in ppix-formation with hyperspectrum camera;Primary end point(s): clinical and histological healing of actinic keratoses;Timepoint(s) of evaluation of this end point: 3 months after the treatment	—

Secondary

Measure	Time frame
Secondary end point(s): changes in ppix-formation;Timepoint(s) of evaluation of this end point: before and during treatment	—

Countries

Finland

Contacts

Public ContactMari Grönroos

Mari Grönroos

mari.gronroos@co.inet.fi

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026